Methotrexate bioavailability

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Van Roon, E N ^a,b   Van De Laar, M A F J ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Bioavailability; Methotrexate; Rheumatoid arthritis

Indexed keywords

ALDEHYDE OXIDASE; ANGIOTENSIN 1 RECEPTOR; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; XANTHINE OXIDASE; CIPROFLOXACIN; FOLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CATABOLISM; CIRCADIAN RHYTHM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MONITORING; DRUG SAFETY; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION; HUMAN; INTESTINE ABSORPTION; LONG TERM CARE; NEPHROTOXICITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STOMACH ABSORPTION; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENETIC VARIATION; JUVENILE RHEUMATOID ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PHARMACOGENETICS; RENAL CLEARANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VOLUME OF DISTRIBUTION;

ANTIRHEUMATIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; METHOTREXATE; POLYGLUTAMIC ACID;

EID: 78650574563     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. U. S. Department of Health and Human Services,, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003, revision 1. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/ Guidanceslucm070124.pdf
2. CHLÁDEK K, MARTÍNKOVÁ J, SIMKOVÁ M et al.: Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998;53:437-44.
3. OGUEY D, KÖLLIKER F, GERBER NJ, REICHEN J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611-4.
4. BANNWARTH B, PEHOURCQ F, SCHAEVERBEKE T, DEHAIS J: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokin 1996;30:194-210.
5. LEBBE C, BEYELER C, GERBER NJ, REICHEN J: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475-7.
6. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, VAN DE LAAR M: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645-8.
7. GODFREY C, SWEENEY K, MILLER K, HAMILTON R, KREMER J: The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
8. SEIDEMAN P, BECK O, EKSBORG S, WENNBERG M: The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;35:409-12.
9. BAGGOTT JE, MORGAN SL: Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum 2009;60:2257-61.
10. CHLÁDEK J, MARTINKOVÁ J, SISPERA L: An in vitro study on methotrexate hydroxylation in rat and human liver. Physiol Res 1997;46:371-9.
11. HERMAN RA, VENG-PEDERSEN P, HOFFMAN J et al.: Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J PharmSci 1909;78:165-71.
12. HAMILTON RA, KREMER JM: The effects of food on methotrexate absorption. J Rheumatol 1995;22:630-2.
13. SHODA H, INOKUMA S, YAIJIMA N, TANAKA Y, OOBAYASHI T, SETOGUCHI K: Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients. Mod Rheumatol 2007;17:311-6.
14. CARPENTIER N, BERTIN P, MARQUET P et al.: Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis. J Rheumatol 1998;25:1270-5.
15. BAGGOTT JE, BRIDGES SL JR, MORGAN SL: Evidence for two phenotypes in the metabolism of methotrexate to-7-hydroxymethotrexate in patients with rheumatoid arthritis. Arthr Rheum 2005;52:356-8.
16. MACK DR, YOUNG R, KAUFMANN SS et al.: Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
17. KREMER JM, PETRILLO GF, HAMILTON RA: Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995;22:38-40.
18. GRIM J, CHLÁDEK J, MARTÍNKOVÁ J: Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003;42:139-51.
19. HENDEL J, BRODTHAGEN H: Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur J Clin Pharmacol 1984;26:103-7.
20. EDNO L, BRESSOLLE F, GOMENI R et al.: Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 1996;18:128-34.
21. TISHLER M, CASPI D, GRAFF E, SEGAL R, PERETZ H, YARON M: Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 1989;28:422-3.
22. LAFFORGUE P, MONJANEL-MOUTERDE S, DURAND A, CATALIN J, ACQUAVIVA PC: Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844-9.
23. TUKOVÁ J, CHLÁDEK J, NEMCOV Á, CHLÁ DKOVÁ J, DOLEZALOVÁ P: Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009;27:1053-9.
24. HAMILTON RA, KREMER JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
25. JUNDT JW, BROWNE BA, FIOCCO GP, STEELE AD, MOCK D: A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
26. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, VAN DE LAAR M: Splitting highdose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 2006;33:481-5.
27. VISSER K, VAN DER HEIJDE D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of literature. Ann Rheum Dis 2009;68:1094-9.
28. ROZIN A, SCHAPIRA D, BALBIR-GURMAN A et al.: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002;61:756-7.
29. BRAUN J, KÄSTNER P, FLAXENBERG P et al.; MC-MTX.6/RH Study: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
30. ALSUFYANI K, ORTIZ-ALVAREZ O, CABRAL DA, TUCKER LB, PETTY RE, MALLESON PN: The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004;31:179-82.
31. VAN ROON EN, VAN DEN BEMT P M L A, JANSEN T L T H A, HOUTMAN NM, VAN DE LAAR M A F J, BROUWERS J R B J: An evidencebased assessment of the clinical significance of drug-drug interactions between diseasemodifying antirheumatic drugs and nonantirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 2009;31:1737-46.
32. TAKEDA M, KHAMDANG S, NARIKAWA S et al.: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302:666-71.
33. NOZAKI Y, KUSUHARA H, ENDOU H, SUGIYAMA Y: Quantitative evaluation of the drugdrug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 2004;309:226-34.
34. MAEDA A, TSURUOKA S, KANAI Y et al.: Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Clin Pharmacol 2008;596:166-72.
35. EL-SHEIKH AA, VAN DEN HEUVEL J J M W, KOENDERINK JB, RUSSEL F G M: Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) (2/ABBC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007;320:229-35.
36. VAN ROON EN, FLIKWEERT S, LE COMTE M et al.: Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005;28:1131-9.
37. TRACY TS, KROHN K, JONES DR, BRADLEY JD, HALL SD, BRATER DC: The effects of salicylate, ibuprofen and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
38. CHLADEK J, SIMKOVÁ, VANECKOVÁ J et al.: The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe-plaque psoriasis. Eur J Clin Pharmacol 2008;64:347-55.
39. VAN EDE AE, LAAN RF, BLOM HJ et al.: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:658-65.
40. HARTMAN M, VAN EDE A, SEVERENS JL, LAAN RF, VAN DE PUTTE L, VAN DER WILT GJ: Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. J Rheumatol 2004;31:902-8.
41. ZARYCHANSKI R, WLODARCZYK K, ARIANO R, BOW E: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J Antimicrob Chemother 2006;58:228-30.
42. DALLE JH, AUVRIGNON A, VASSAL G, LEVERGER G: Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002;24:321-2.
43. SUZUKI K, DOKI K, HOMMA M et al.: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2008;67:44-9.
44. HAMILTON SF, CAMPBELL N R C, KARA M, WATSON J, CONNORS M: The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis. J Rheumatol 2003;30:1948-50.
45. VAKILY M, AMER F, KUKULKA MJ, ANDHIVAROTHAI N: Coadministration of lansopazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis 2005;45:1179-86.
46. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN FT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
47. STAMP LK, O'DONNELL JL, CHAPMAN PT et al.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010;62:359-68.
48. HROCH M, CHLADEK J, SIMKOVA M, VANECKOVA J, GRIM J, MARTINKOVA J: A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereal 2008;22:19-24.